Juntendo & OrganoTherapeutics collaborate with patient samples
Patient specific stem cell lines are the foundation for the development of the brain organoid model that OrganoTherapeutics uses to develop new therapeutics against Parkinson’s disease. Hence, having available a broad spectrum of these stem cell lines from different individuals, with different PD associated mutations and different genetic backgrounds is a key prerequisite for the success of this endeavor. The newly concluded alliance between Juntendo University in Tokyo and OrganoTherapeutics, now allows OrganoTherapeutics to make use of various stem cell lines that have been generated at Juntendo. OrganoTherapeutics CEO, Jens Schwamborn mentions “Juntendo University is a world leading institution in PD research. Partnering with such a powerhouse is an immense honor for us. Further, the cell lines that we get from Juntendo are extremely valuable for us and will certainly accelerate our therapeutics developments. We are very grateful for this important collaboration.” Chair and Professor of Juntendo University, Nobutaka Hattori mentions “We work with collaborators around the world to bring better treatments to patients with Parkinson's disease. Through this partnership with OrganoTherapeutics, a frontrunner in the development of therapeutics using iPSC-derived organoids, we are excited about the development of new therapies.”
About Juntendo University:
Juntendo University was founded in 1838 as the oldest Western medical school in Japan. The Department of Neurology at Juntendo University has focused on the treatment and research of Parkinson's disease for many years. They have made many research contributions, including the discovery of three PARK PD-related genes, a blood-based PD diagnostic method, and studies using patient-derived iPS cells. Their goal is to provide more optimal treatment for all patients through the development of these studies.
About OrganoTherapeutics:
OrganoTherapeutics (OT) is a spin-off biotech company from the University of Luxembourg and the Luxembourg center for Systems Biomedicine. Founded in 2019, OT aims at further developing brain organoid systems and using them for therapeutics development in Parkinson’s disease. The OT approach is based on phenotypic screening and AI based data analysis. The company is well embedded in the Luxembourgish research landscape, collaborates with leading institutions through European networks and has established partnerships with universities, biotech and pharma companies in Europe, Japan and the US.